Aegerion Pharmaceuticals, Inc.

Quick facts

Phase 3 pipeline

• AEGR-733 · Cardiovascular / Lipidology
  AEGR-733 is a microsomal triglyceride transfer protein (MTP) inhibitor that reduces the production and secretion of apolipoprotein B-containing lipoproteins.

Phase 2 pipeline

• AEGR-733 and atorvastatin · Cardiovascular
  AEGR-733 is a microsomal triglyceride transfer protein (MTP) inhibitor, and atorvastatin is a HMG-CoA reductase inhibitor.
• AEGR-733 and ezetimibe
• AEGR-733 and fenofibrate · Cardiovascular
  AEGR-733 is a microsomal triglyceride transfer protein (MTP) inhibitor combined with fenofibrate, a peroxisome proliferator-activated receptor alpha (PPARα) agonist, to reduce triglycerides and apolipoprotein B-containing lipoproteins.

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Aegerion Pharmaceuticals, Inc. portfolio CI brief
• Aegerion Pharmaceuticals, Inc. pipeline updates RSS